Polymeric Nanoparticles Targeting TNF-α in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using TNF-α face systemic side effects, limiting the effectiveness of TNF-α in treating cancers due to its systemic toxicity, and existing delivery methods fail to effectively target tumor cells while minimizing systemic impact.
Innovation Solution
Development of biodegradable polymeric nanoparticles composed of PLA and PEG, loaded with TNF-α protein or nucleic acid encoding TNF-α, which are designed to target and deliver TNF-α specifically to tumor cells, reducing systemic toxicity and enhancing anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNF-α is administered systemically to treat cancer, then anti-tumor activity is improved, but systemic toxicity increases causing severe side effects
Solution Approach 1:
The patent divides the systemic distribution of TNF-α into targeted delivery to tumor cells only. The nanoparticle system segments the therapeutic effect by accumulating specifically at the tumor site through EPR effect and active targeting, leaving healthy tissues unaffected. This resolves the contradiction by maintaining anti-tumor activity while eliminating systemic toxicity through spatial segmentation of drug distribution.
Solution Approach 2:
The patent introduces polymeric nanoparticles as an intermediary carrier between the TNF-α drug and the target tumor cells. These nanoparticles serve as a mediator that protects TNF-α from premature degradation, enables controlled release, and facilitates targeted delivery through surface functionalization with targeting ligands. The intermediary nanoparticle system resolves the toxicity issue while preserving therapeutic efficacy.
2Ease of operation
If conventional delivery methods are used to administer TNF-α, then treatment simplicity is maintained, but targeting precision to tumor cells deteriorates
Solution Approach 1:
The patent creates a universal nanoparticle platform that combines multiple functions: passive targeting via EPR effect, active targeting through surface ligands, controlled release mechanism, and protection of therapeutic agent. This multi-functional system achieves high targeting precision while maintaining ease of administration as a single intravenous injection, resolving the contradiction between simplicity and precision.
Solution Approach 2:
The patent employs composite polymeric nanoparticles composed of biodegradable polymers (PLA, PEG-PLA) with surface-functionalized targeting ligands. This composite material structure integrates the benefits of biodegradability, controlled release, and active targeting in a single formulation. The composite nature enables both ease of operation and high targeting precision simultaneously.
3Reliability
If high doses of TNF-α are administered to overcome resistance, then anti-tumor effectiveness is improved, but systemic side effects worsen
Solution Approach 1:
The patent applies local quality by concentrating high concentrations of TNF-α specifically at the tumor site through nanoparticle accumulation, while maintaining low or zero concentrations in systemic circulation. The EPR effect and active targeting mechanisms ensure that the high dose required for effectiveness is delivered locally to tumors, resolving the contradiction between achieving anti-tumor effectiveness and avoiding systemic side effects through spatial differentiation of drug concentration.
Data Source
AI summary
The present invention relates to polymeric nanoparticles comprising a cytokine or a nucleic acid encoding for a cytokine, pharma-ceutical compositions comprising the same, and methods for treating certain diseases comprising administering these polymeric nanoparticles to a subject in need thereof.